13 of the World’s Leading Biopharma Companies Adopt Veeva Link Key People for Enhanced Engagement

In a noteworthy development, Veeva Systems (NYSE: VEEV) has announced that 13 out of the top 20 biopharmaceutical companies worldwide have integrated Veeva Link Key People into their operations. This strategic move is aimed at strengthening customer engagement and enhancing data accessibility, particularly as these firms increasingly turn to artificial intelligence (AI) to meet their objectives in the increasingly competitive biopharma sector.

The Impact of Veeva Link Key People

Veeva Link Key People provides biopharma companies with reliable insights that are essential for data-driven decision-making. With the ongoing implementation, it is reported that 38 new customers have registered to adopt Link Key People, with three of the industry’s largest firms incorporating it as a global standard just in the last year. This escalating reliance on Veeva’s technology underscores its critical role in the strategy of top-tier biopharmaceutical firms as they navigate a landscape defined by rapid change and the need for heightened accountability and strategic vision.

Dr. Daniel Jardanhazi-Kurutz, the Deputy Director of Customer Engagement at Bayer AG, expressed that, "Access to Veeva Link Key People strengthens data-driven decision-making, improves targeting accuracy, and fosters interaction with healthcare representatives, ultimately benefiting patient care. The Link Key People data has become an integral part of Bayer's data DNA, enriching the outcomes of our agent-based, AI-driven platforms and providing more relevant and actionable business insights that benefit patients long-term."

Transforming Client Interactions

Link Key People delivers substantial value to both medical and commercial teams by ensuring they have access to trusted information. Meanwhile, analytics teams can leverage Link data as a foundational element for their AI models. Recent innovations—including AI-driven summaries and tailored notifications—amplify customer interactions and offer new avenues to discover customer engagement opportunities. Furthermore, the Link Direct Data API grants data teams rapid access to a new class of APIs that Veeva has introduced, further expediting data retrieval and utilizing technology for strategic advantage.

David Medina Tato, Vice President of Strategy for Link Key People at Veeva, commented, "Trusted customer insights are pivotal for advancing AI and contribute substantially to achieving launch performance. As more leading biopharmaceutical firms and emerging biotech companies harness the capabilities of Link Key People, we will continue to inform and enhance engagement across the industry with profound KOL (Key Opinion Leader) data to foster strategic and impactful relationships."

Integration into a Broader Ecosystem

Link Key People is part of the Veeva Data Cloud, which includes other essential tools such as Veeva OpenData, Veeva HCP 360, and Veeva Compass. The platform utilizes Veeva's Common Data Architecture (CDA), seamlessly connecting software and data to enhance operational efficiency and decision-making processes.

As Veeva Systems continues to push the envelope in data service and client engagement tools, its approach remains grounded in supporting the needs of its 1,500+ clients ranging from global pharmaceutical giants to rapidly advancing biotech firms. As a Public Benefit Corporation, Veeva remains committed to harmonizing the interests of all stakeholders—including customers, employees, shareholders, and the broader industry it serves.

Conclusion

By standardizing on Veeva Link Key People, these top-tier biopharmaceutical companies are not only embracing innovation but also positioning themselves at the forefront of a data-driven era where healthcare outcomes can be markedly improved through strategic customer engagement. As this trend continues, we can expect even greater integration of AI and data services within the biopharma industry, highly influenced by solutions like Veeva Link Key People.